|
1.
|
Merritt MA and Cramer DW: Molecular
pathogenesis of endometrial and ovarian cancer. Cancer Biomark.
9:287–305. 2010.PubMed/NCBI
|
|
2.
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
3.
|
Hobert JA and Eng C: PTEN hamartoma tumor
syndrome: an overview. Genet Med. 11:687–694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Conti S, Condò M, Posar A, et al:
Phosphatase and tensin homolog (PTEN) gene mutations and autism:
literature review and a case report of a patient with Cowden
syndrome, autistic disorder, and epilepsy. J Child Neurol.
27:392–397. 2012. View Article : Google Scholar
|
|
5.
|
Litzendorf M, Hoang K and Vaccaro P:
Recurrent and extensive vascular malformations in a patient with
Bannayan-Riley-Ruvalcaba syndrome. Ann Vasc Surg.
25:1138.e15-92011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Knobbe CB, Merlo A and Reifenberger G:
Pten signaling in gliomas. Neuro Oncol. 4:196–211. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Li FP, Fraumeni JF Jr, Mulvihill JJ, et
al: A cancer family syndrome in twenty-four kindreds. Cancer Res.
48:5358–5362. 1988.PubMed/NCBI
|
|
9.
|
Masui K, Cloughesy TF and Mischel PS:
Review: molecular pathology in adult high-grade gliomas: from
molecular diagnostics to target therapies. Neuropathol Appl
Neurobiol. 38:271–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dong JT: Prevalent mutations in prostate
cancer. J Cell Biochem. 97:433–447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Chen Z, Trotman LC, Shaffer D, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kim J, Eltoum IE, Roh M, Wang J and
Abdulkadir SA: Interactions between cells with distinct mutations
in c-MYC and Pten in prostate cancer. PLoS Genet. 5:e10005422009.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Blanco-Aparicio C, Renner O, Leal JF and
Carnero A: PTEN, more than the AKT pathway. Carcinogenesis.
28:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Faesen AC, Dirac AM, Shanmugham A, Ovaa H,
Perrakis A and Sixma TK: Mechanism of USP7/HAUSP activation by its
C-terminal ubiquitin-like domain and allosteric regulation by
GMP-synthetase. Mol Cell. 44:147–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sacco JJ, Coulson JM, Clague MJ and Urbé
S: Emerging roles of deubiquitinases in cancer-associated pathways.
IUBMB Life. 62:140–157. 2010.
|
|
16.
|
Okumura N, Yoshida H, Kitagishi Y,
Murakami M, Nishimura Y and Matsuda S: PI3K/AKT/PTEN signaling as a
molecular target in leukemia angiogenesis. Adv Hematol.
2012.8430852012.PubMed/NCBI
|
|
17.
|
Okumura N, Yoshida H, Kitagishi Y,
Nishimura Y and Matsuda S: Alternative splicings on p53, BRCA1 and
PTEN genes involved in breast cancer. Biochem Biophys Res Commun.
413:395–399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Croushore JA, Blasiole B, Riddle RC, et
al: Pten a and pten b genes play distinct roles in zebrafish
embryogenesis. Dev Dyn. 234:911–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Teresi RE, Shaiu CW, Chen CS, Chatterjee
VK, Waite KA and Eng C: Increased PTEN expression due to
transcriptional activation of PPARgamma by Lovastatin and
Rosiglitazone. Int J Cancer. 118:2390–2398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Shen YH, Zhang L, Gan Y, et al:
Up-regulation of PTEN (phosphatase and tensin homolog deleted on
chromosome ten) mediates p38 MAPK stress signal-induced inhibition
of insulin signaling. A cross-talk between stress signaling and
insulin signaling in resistin-treated human endothelial cells. J
Biol Chem. 281:7727–7736. 2006.
|
|
21.
|
Pan L, Lu J, Wang X, et al: Histone
deacetylase inhibitor trichostatin a potentiates
doxorubicin-induced apoptosis by up-regulating PTEN expression.
Cancer. 109:1676–1688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Lee YR, Yu HN, Noh EM, et al: Peroxisome
proliferator-activated receptor gamma and retinoic acid receptor
synergistically up-regulate the tumor suppressor PTEN in human
promyeloid leukemia cells. Int J Hematol. 85:231–237. 2007.
View Article : Google Scholar
|
|
23.
|
Yang Y, Zhou F, Fang Z, et al:
Post-transcriptional and post-translational regulation of PTEN by
transforming growth factor-beta1. Cell Biochem. 106:1102–1112.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Han S, Ritzenthaler JD, Zheng Y and Roman
J: PPARbeta/delta agonist stimulates human lung carcinoma cell
growth through inhibition of PTEN expression: the involvement of
PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol.
294:L1238–L1249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vasudevan KM, Burikhanov R, Goswami A and
Rangnekar VM: Suppression of PTEN expression is essential for
antiapoptosis and cellular transformation by oncogenic Ras. Cancer
Res. 67:10343–10350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Yoshida H, Okumura N, Kitagishi Y,
Nishimura Y and Matsuda S: Ethanol extract of rosemary repressed
PTEN expression in K562 culture cells. Int J Appl Boil Pharm
Technol. 2:316–322. 2011.
|
|
27.
|
Mueller S, Phillips J, Onar-Thomas A, et
al: PTEN promoter methylation and activation of the PI3K/Akt/mTOR
pathway in pediatric gliomas and influence on clinical outcome.
Neuro Oncol. 14:1146–1152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Faurschou A, Gniadecki R, Calay D and Wulf
HC: TNF-alpha impairs the S-G2/M cell cycle checkpoint and
cyclobutane pyrimidine dimer repair in premalignant skin cells:
role of the PI3K-Akt pathway. J Invest Dermatol. 128:2069–2077.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Chen Y, Wang BC and Xiao Y: PI3K: a
potential therapeutic target for cancer. J Cell Physiol.
227:2818–2821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Choi Y, Zhang J, Murga C, et al: PTEN, but
not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces
growth inhibition and apoptosis of myeloma cells. Oncogene.
21:5289–5300. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Petrella BL and Brinckerhoff CE: PTEN
suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null
renal-cell carcinoma. Cancer Biol Ther. 8:1389–1401. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yamamoto M, Tamakawa S, Yoshie M, Yaginuma
Y and Ogawa K: Neoplastic hepatocyte growth associated with cyclin
D1 redistribution from the cytoplasm to the nucleus in mouse
hepatocarcinogenesis. Mol Carcinog. 45:901–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Andrés-Pons A, Gil A, Oliver MD, Sotelo NS
and Pulido R: Cytoplasmic p27Kip1 counteracts the pro-apoptotic
function of the open conformation of PTEN by retention and
destabilization of PTEN outside of the nucleus. Cell Signal.
24:577–587. 2012.PubMed/NCBI
|
|
34.
|
Planchon SM, Waite KA and Eng C: The
nuclear affairs of PTEN. J Cell Sci. 121:249–253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Palmero EI, Achatz MI, Ashton-Prolla P,
Olivier M and Hainaut P: Tumor protein 53 mutations and inherited
cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 22:64–69.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Freeman DJ, Li AG, Wei G, et al: PTEN
tumor suppressor regulates p53 protein levels and activity through
phosphatase-dependent and -independent mechanisms. Cancer Cell.
3:117–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Lo PK, Lee JS and Sukumar S: The
p53-p21WAF1 checkpoint pathway plays a protective role in
preventing DNA rereplication induced by abrogation of FOXF1
function. Cell Signal. 24:316–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Puszyński K, Hat B and Lipniacki T:
Oscillations and bistability in the stochastic model of p53
regulation. J Theor Biol. 254:452–465. 2008.PubMed/NCBI
|
|
39.
|
Eitel JA, Bijangi-Vishehsaraei K,
Saadatzadeh MR, et al: EN and p53 are required for hypoxia induced
expression of maspin in glioblastoma cells. Cell Cycle. 8:896–901.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Zhang M: PTEN in action: coordinating with
p53 to regulate maspin gene expression. Cell Cycle. 8:1112–1113.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Wang X and Jiang X: Mdm2 and MdmX partner
to regulate p53. FEBS Lett. 586:1390–1396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Levav-Cohen Y, Haupt S and Haupt Y: Mdm2
in growth signaling and cancer. Growth Factors. 23:183–192. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Mayo LD and Donner DB: The PTEN, Mdm2, p53
tumor suppressor-oncoprotein network. Trends Biochem Sci.
27:462–467. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Kirch HC, Flaswinkel S, Rumpf H, Brockmann
D and Esche H: Expression of human p53 requires synergistic
activation of transcription from the p53 promoter by AP-1,
NF-kappaB and Myc/Max. Oncogene. 18:2728–2738. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Zheng T, Meng X, Wang J, et al: PTEN- and
p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric
cancer cells and nude mice. J Cell Biochem. 111:218–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Mayo LD, Dixon JE, Durden DL, Tonks NK and
Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells
to chemotherapy. J Biol Chem. 277:5484–5489. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Sen P, Mukherjee S, Ray D and Raha S:
Involvement of the Akt/PKB signaling pathway with disease
processes. Mol Cell Biochem. 253:241–246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Li AG, Piluso LG, Cai X, Wei G, Sellers WR
and Liu X: Mechanistic insights into maintenance of high p53
acetylation by PTEN. Mol Cell. 23:575–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Quevedo C, Kaplan DR and Derry WB: AKT-1
regulates DNA-damage-induced germline apoptosis in C.
elegans. Curr Biol. 17:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Ming M and He YY: PTEN in DNA damage
repair. Cancer Lett. 319:125–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Bonavida B and Baritaki S: The novel role
of Yin Yang 1 in the regulation of epithelial to mesenchymal
transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN
circuitry. Crit Rev Oncog. 16:211–226. 2011.
|
|
53.
|
Vu BT and Vassilev L: Small-molecule
inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol.
348:151–172. 2011.PubMed/NCBI
|
|
54.
|
Bixby D, Kujawski L, Wang S and Malek SN:
The pre-clinical development of MDM2 inhibitors in chronic
lymphocytic leukemia uncovers a central role for p53 status in
sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle.
7:971–979. 2008. View Article : Google Scholar
|
|
55.
|
Amodio N, Scrima M, Palaia L, et al:
Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative
regulator, in non-small-cell lung carcinomas. Am J Pathol.
177:2622–2634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Valiente M, Andrés-Pons A, Gomar B, et al:
Binding of PTEN to specific PDZ domains contributes to PTEN protein
stability and phosphorylation by microtubule-associated
serine/threonine kinases. J Biol Chem. 280:28936–28943. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Torres J and Pulido R: The tumor
suppressor PTEN is phosphorylated by the protein kinase CK2 at its
C terminus. Implications for PTEN stability to proteasome-mediated
degradation. J Biol Chem. 276:993–998. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Wu W, Wang X, Zhang W, et al: Zinc-induced
PTEN protein degradation through the proteasome pathway in human
airway epithelial cells. J Biol Chem. 278:28258–28263. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Li Y, Ozaki T, Kikuchi H, Yamamoto H,
Ohira M and Nakagawara A: A novel HECT-type E3 ubiquitin protein
ligase NEDL1 enhances the p53-mediated apoptotic cell death in its
catalytic activity-independent manner. Oncogene. 27:3700–3709.
2008. View Article : Google Scholar
|
|
60.
|
Shinada K, Tsukiyama T, Sho T, Okumura F,
Asaka M and Hatakeyama S: RNF43 interacts with NEDL1 and regulates
p53-mediated transcription. Biochem Biophys Res Commun.
404:143–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Barata JT: The impact of PTEN regulation
by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv
Enzyme Regul. 51:37–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Kang JY, Kim JJ, Jang SY and Bae YS: The
p53-p21(Cip1/WAF1) pathway is necessary for cellular senescence
induced by the inhibition of protein kinase CKII in human colon
cancer cells. Mol Cells. 28:489–494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Marsh DJ, Kum JB, Lunetta KL, et al: PTEN
mutation spectrum and genotype-phenotype correlations in
Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with
Cowden syndrome. Hum Mol Genet. 8:1461–1472. 1999. View Article : Google Scholar
|
|
64.
|
Marsh DJ, Coulon V, Lunetta KL, et al:
Mutation spectrum and genotype-phenotype analyses in Cowden disease
and Bannayan-Zonana syndrome, two hamartoma syndromes with germline
PTEN mutation. Hum Mol Genet. 7:507–515. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Zbuk KM and Eng C: Hamartomatous polyposis
syndromes. Nat Clin Pract Gastroenterol Hepatol. 4:492–502. 2007.
View Article : Google Scholar
|
|
66.
|
Agrawal S, Pilarski R and Eng C: Different
splicing defects lead to differential effects downstream of the
lipid and protein phosphatase activities of PTEN. Hum Mol Genet.
14:2459–2468. 2005. View Article : Google Scholar
|
|
67.
|
Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA
and Eng C: Cowden syndrome-affected patients with PTEN promoter
mutations demonstrate abnormal protein translation. Am J Hum Genet.
81:756–767. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Han SY, Kato H, Kato S, et al: Functional
evaluation of PTEN missense mutations using in vitro
phosphoinositide phosphatase assay. Cancer Res. 60:3147–3151.
2000.PubMed/NCBI
|
|
69.
|
Kato H, Kato S, Kumabe T, et al:
Functional evaluation of p53 and PTEN gene mutations in gliomas.
Clin Cancer Res. 6:3937–3943. 2000.PubMed/NCBI
|
|
70.
|
Georgescu MM, Kirsch KH, Kaloudis P, Yang
H, Pavletich NP and Hanafusa H: Stabilization and productive
positioning roles of the C2 domain of PTEN tumor suppressor. Cancer
Res. 60:7033–7038. 2000.PubMed/NCBI
|
|
71.
|
Trotman LC, Wang X, Alimonti A, et al:
Ubiquitination regulates PTEN nuclear import and tumor suppression.
Cell. 128:141–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Bonneau D and Longy M: Mutations of the
human PTEN gene. Hum Mutat. 16:109–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Keniry M and Parsons R: The role of PTEN
signaling perturbations in cancer and in targeted therapy.
Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Simpson L and Parsons R: PTEN: life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Carracedo A, Alimonti A and Pandolfi PP:
PTEN level in tumor suppression: how much is too little? Cancer
Res. 71:629–633. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Alimonti A, Carracedo A, Clohessy JG, et
al: Subtle variations in Pten dose determine cancer susceptibility.
Nat Genet. 42:454–458. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Xie CC, Lu L, Sun J, et al: Germ-line
sequence variants of PTEN do not have an important role in
hereditary and non-hereditary prostate cancer susceptibility. J Hum
Genet. 56:496–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Riegert-Johnson DL, Gleeson FC, Roberts M,
Tholen K, Youngborg L, Bullock M and Boardman LA: Cancer and
Lhermitte-Duclos disease are common in Cowden syndrome patients.
Hered Cancer Clin Pract. 8:62010. View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Ali E, Athanasopoulos PG, Forouhi P and
Malata CM: Cowden syndrome and reconstructive breast surgery: case
reports and review of the literature. J Plast Reconstr Aesthet
Surg. 64:545–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Zhang G, Yang P, Guo P, Miele L, Sarkar
FH, Wang Z and Zhou Q: Unraveling the mystery of cancer metabolism
in the genesis of tumor-initiating cells and development of cancer.
Biochim Biophys Acta. 1836:49–59. 2013.PubMed/NCBI
|
|
81.
|
Dean JL and Knudsen KE: The role of tumor
suppressor dysregulation in prostate cancer progression. Curr Drug
Targets. 14:460–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
